PF4 and COVID-19: Notably, as mentioned in the Introduction, transient anti-PF4 antibodies have been demonstrated in 30 to 75% of adenovirus-vectored COVID-19 vaccinees, though autoimmune coagulopathies have remained extremely rare (24, 27, 29).